Our hematology and oncology research experts have the experience and expertise to guide your clinical trials.
Vice President, Oncology, Clinical Development Services
Luke Gill has an extensive scientific background and more than 20 years of drug development experience. Specializing in oncology, he has led numerous global CRO management teams and provided strategic assessment, management, and oversight of study enrollment and program metrics.
Prior to joining Premier Research in 2015, Mr. Gill was Director of Global Project Management for Hematology and Oncology at PPD, overseeing design and delivery of clinical development plans across multiple indications and specializing in early-phase oncology. He also served as Assistant Project Management Director at PPD, was CRO alliance program director for Merck Serono, and has held positions at Pfizer/Parke Davis, Astra, and Glaxo.
Mr. Gill holds a master’s degree in neuro and molecular pharmacology from the University of Bristol, a bachelor’s degree in biological sciences from the University of the West of England, and an MBA specializing in strategy and international enterprise from the Open University in the U.K.
Senior Medical Director, Hematology-Oncology
Peter Larson, M.D., is Senior Medical Director for Hematology-Oncology. Dr. Larson supports the drug development work of the innovative biotech companies that comprise most of Premier Research’s customer base, bringing to the role extensive clinical and medical affairs experience.
With a background spanning large pharma, startup biotech, and contract research, Dr. Larson was Senior Director of Clinical Research at pharmaceutical start-up Chimerix Inc. before joining Premier Research in 2016. Prior to that, he was Senior Director of Oncology Global Medical Affairs at Novartis Pharmaceutical Corporation.
Dr. Larson also held senior positions at F. Hoffmann-La Roche AG, where he led the company’s global virology franchise, and Bayer Corporation, where he was head of global clinical strategy. He also was Assistant Professor of Pediatrics at the University of Pennsylvania. Dr. Larson’s therapeutic expertise includes hematology, oncology, hemophilia, mastocytosis, AML, ALL, multiple myeloma, GIST, and virology.
He holds a Doctor of Medicine and a bachelor’s degree in biology from the University of North Carolina and is a fellow in transfusion medicine, blood banking, and hematology at University of North Carolina Hospitals.
Chief Medical Officer
As CMO of Premier Research, Dr. Colin Hayward is responsible for leading the scientific strategy of Premier Research directly overseeing the medical, safety, regulatory, and medical writing teams. Dr. Hayward re-joined Premier Research after 18 months gaining experience in oncology diagnostics and companion diagnostics as European Medical Director for Myriad Genetics. Before his initial spell with Premier Research as Vice President, Medical Affairs, Dr. Hayward ran a medical affairs consultancy business, Prism Ideas. He also worked for eight years at Roche starting with his last appointments as international medical leadership roles for global oncology products.
Dr. Hayward has extensive experience in the late development of a number of oncology and hemato-oncology compounds including NHL, breast, ovarian, renal, lung and prostate cancer as well as oncology diagnostics.
Dr. Hayward gained his medical degree from the University of Guy’s and St. Thomas’s Hospitals in 1994. He practiced in the National Health Service before joining the pharmaceutical industry and specializing in pharmaceutical medicine going onto the specialist register of the General Medical Council in 2011. He is interested in the education and development of pharmaceutical medicine and is an appraiser and fellow of the Faculty of Pharmaceutical Medicine.
Associate Director, Oncology, Strategic Development
Stephan Laux has more than 25 years of global CRO and pharmaceutical experience in a wide range of therapeutic areas, with concentrated expertise in oncology and hematology, dermatology, rheumatology, transplant medicine, and infectious diseases. He joined Premier Research in 2008 as a project manager and led numerous international and global clinical trials prior to assuming his current position in 2016.
Dr. Laux has an extensive oncology background and maintains a large network of key opinion leaders in the field. He has led many oncology trials, from Phase I to Phase III, with a focus on hematological oncology, non-Hodgkin lymphoma, and prostate cancer, and has a special interest in PK/PD models and PK simulation models.
Prior to joining Premier Research, Dr. Laux held program management positions at PPD, Hesperion International, and Medifacts International, and worked as a clinical trial leader and clinical research associate. He holds a Ph.D. from the University of Heidelberg in Germany and is a member of the Union for International Cancer Control and the German Cancer Aid Foundation.
Senior Director, Program Delivery
Brian Marks is a Senior Director, Project Delivery in Oncology. Brian oversees and manages the program team to ensure program progress is according to client and Premier Research requirements and recommends and drives necessary courses of action to keep programs on track. Brian oversees and chairs OMCs and Joint Steering Committees as key team member with customers, monitors the health and growth of mission-critical accounts and assists in the creation, development, and nurturing of key strategic customer relationships. Brian has also worked as a Director of Strategic Initiative Management, Director of Project Management and a Senior PM at ICON clinical research. At GlaxoSmithKline, Brian Marks was a Manager of Study Management, Program Lead and a Lead Study Manager. Brian was a Clinical Research Monitor at both Ingenix Pharmaceutical Services and PPD.
Brian’s experience with Global Oncology studies include the following Phase and indications Phases II, IIb/III, Acute Myeloid Leukemia (AML), Phase II, Non-Small Cell Lung Cancer, Phases I, II, IIb/III, IV Breast Cancer, Phases I Ovarian Cancer (US only) and Phase IV Oncologic Pain. Brian also has global respiratory experience in Phases II/IIb/III/IV (Exploratory Biomarkers) for COPD, Phases IIb/III, IV Asthma and Phases IIb/III, IV Allergy (Pediatric and Adult). Brian has experience in US only (Influenza Phase II) and Global Phases II, III Pneumonia and Phases II, III Meningitis B. As a clinical research associate, Brian monitored US and Global Phase IV Bipolar Disease, Phase IV NIDDM and Phase III, IV Cardiovascular (Device), obesity, osteoarthritis.
Brian Marks received his Doctorate in Chiropractic as well as his Bachelors in Science in Human Biology from Logan College of Chiropractic. Brian also received his Bachelors in Arts in Psychology from the State University of New York at Albany.
In addition to his College and University degrees, Brian has also earned a Certification as Chiropractic Sports Physician (CCSP) from NY College of Chiropractic and a Certification in Hypnotherapy from the Hypnosis Motivation Institute in California.